Research Impact – Bench to bedside – CDK4/6 inhibitor for prostate cancer in trial
Professor Butler now leads the Prostate Cancer Research Group at SAHMRI which focuses on therapeutics and lipids in prostate cancer. Nearly five years later and with funding from Cancer Australia, Professor Butler and with medical oncologist Professor Lisa Horvath from the Chris O’Brien Lifehouse in NSW, are now testing the safety and potential effect of the same CDK4/6 inhibitor (ribociclib) in an early phase clinical trial in men undergoing surgery for high risk, localised prostate cancer. THese CDK4/6 inhibitors are already being used to treat women with breast cancer.
It is hoped this research will help demonstrate the activity of this drug against prostate cancers, and lay the groundwork for more trials.
This entry was posted in News, Research and tagged CDK4/6, clinical trial, prostate cancer, therapeutics. Bookmark the permalink.
Comments are closed.